Midatech Pharma (LON:MTPH) Sets New 12-Month Low at $2.20
Shares of Midatech Pharma PLC (LON:MTPH) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 2.20 ($0.03) and last traded at GBX 2.25 ($0.03), with a volume of 950319 shares trading hands. The stock had previously closed at GBX 2.40 ($0.03).
The company has a debt-to-equity ratio of 4.42, a current ratio of 4.21 and a quick ratio of 3.83. The business has a 50-day simple moving average of GBX 3.46 and a 200-day simple moving average of GBX 5.23. The firm has a market capitalization of $11.04 million and a PE ratio of -0.53.
In related news, insider Stephen Stamp acquired 100,000 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were acquired at an average cost of GBX 6 ($0.08) per share, for a total transaction of £6,000 ($7,892.66).
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer.
Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.